304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2023-05-05

IND application of phase 2 clinical trial of HANSIZHUANG in combination with novel anti-LAG-3 mAb and chemotherapy for the first-line treatment of advanced non-small cell lung cancer patients was approved by NMPA
2023-04-26

A Solid Foundation of Sustainability, Henlius Releases 2022 ESG Report
2023-04-16

Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged
2023-04-06

CDE Grants Breakthrough Therapy Designation to Henlius BRAF Inhibitor HLX208
2023-03-31

Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues
2023-03-23

EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab)
2023-03-17

Cell’s trends reviews journal published the regulatory differences of Henlius' biosimilar for approval between Europe and China
2023-03-15

Henlius Novel anti-OX40 HLX51 Received Clinical Trial Approval in China
2023-02-15

Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02